A Phase 2 interventional study of Ertugliflozin and Placebo in Type 2 Diabetes Mellitus and Heart Failure, sponsored by University Health Network, Toronto. Completed at 3 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 18th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,438 studies on the registry; 295 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
14 studies in Diabetes Mellitus, Type 2 by University Health Network, Toronto: 2 open now, 2 under way, none of them phase 3. Of 9 finished, 3 (33%) have results posted.
Among the 14 studies in Diabetes Mellitus, Type 2 by University Health Network, Toronto, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2, and was the 10th registered.
University Health Network, Toronto’s Diabetes Mellitus, Type 2 studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University Health Network, Toronto’s 14 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).
Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also reduce blood pressure and albuminuria in T2D - possibly through natriuresis. Importantly, a landmark trial "EMPA-REG OUTCOME" demonstrated that the SGLT2i "empagliflozin" is the first anti- hyperglycemic agent to reduce mortality and HF risk, and also to decrease the risk of progressive diabetic nephropathy. Similar benefits were also recently reported in the CANVAS Program trial with canagliflozin. Despite the benefits observed in these two pivotal trials, the mechanisms responsible for beneficial effects of SGLT2i in patients with T2D with respect to the development and/or worsening of HF are not currently known.
In light of the results of EMPA-REG OUTCOME, the investigators aim to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with T2D and HF (T2D-HF). The investigators will test the hypothesis that ertugliflozin increases proximal tubular natriuresis, thereby reducing plasma volume, without inducing significant renal vasoconstriction or activation of the sympathetic nervous system (SNS) (see below, Figure 1). The systematic understanding of the effects of SGLT2i in the setting of HF will enable the design of rational physiology based strategies to decrease the burden of HF, which could have major clinical and research implications internationally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
Drug: Ertugliflozin
Placebo Matching Ertugliflozin Tablet for 12 weeks
Drug: Placebo
Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
Placebo once daily for 12 weeks
Fractional Excretion of Lithium (FELi)
The difference in fractional excretion of lithium (FELi) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before lithium excretion was measured in urine and blood.
Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Fractional Excretion of Sodium (FENa)
The difference in fractional excretion of sodium (FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.
Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Change in Absolute Fractional Distal Sodium Reabsorption From Baseline (FELi-FENa)
The difference in fractional excretion of lithium and fractional excretion of sodium (calculated by the difference between FELi and FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.
Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Glomerular Filtration Rate (GFR)
The difference in iohexol-measured GFR with ertugliflozin vs. placebo. 5ml bolus iohexol (Omnipaque 300mg) was infused intravenously over 2 minutes while participants were supine. Iohexol disappearance curve was used to measure GFR over from 2-4 hours after infusion.
Time frame: Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 12 weeks
Effective Renal Plasma Flow (ERPF)
The difference in ERPF with ertugliflozin vs. placebo. Paraaminohippurate (PAH) was intravenously administered to measured ERPF.
Time frame: Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at 12 weeks
Systolic Blood Pressure (SBP)
The difference in seated SBP with ertugliflozin vs. placebo
Time frame: chronic (12 weeks)
Diastolic Blood Pressure (DBP)
The difference in seated DBP with ertugliflozin vs. placebo
Time frame: chronic (12 weeks)
Heart Rate (HR)
The difference in seated HR with ertugliflozin vs. placebo
Time frame: chronic (12 weeks)
LV Ejection Fraction
Echocardiography for markers of systolic and diastolic function
Time frame: chronic (12 weeks)
Carotid-femoral Pulse Wave Velocity
Arterial Stiffness using SphygmaCor software. Pulse points measured at carotid and femoral arteries.
Time frame: chronic (12 weeks)
Plasma Volume
Plasma volume will be measured using a non-radioactive technique (indocyanine green dilution)
Time frame: chronic (12 weeks)
Extracellular Water
Extracellular water will be measured non-invasively using bioimpedence spectroscopy
Time frame: chronic (12 weeks)
Cardiac Output
Cardiac output will also be measured using non-invasive cardiac monitoring (NICOM)
Time frame: chronic (12 weeks)
Systemic Vascular Resistance
Systemic vascular resistance will also be measured using non-invasive cardiac monitoring (NICOM)
Time frame: chronic (12 weeks)
Blood Angiotensin II
Neurohormones/biomarkers
Time frame: chronic (12 weeks)
BNP
Neurohormones/biomarkers
Time frame: chronic (12 weeks)
Norepinephrine
Neurohormones/biomarkers
Time frame: chronic (12 weeks)
Urinary Adenosine
Neurohormones/biomarkers
Time frame: chronic (12 weeks)
| Milestone | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Started | 17 | 17 |
| Completed | 17 | 16 |
| Not completed | 0 | 1 |
The difference in fractional excretion of lithium (FELi) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before lithium excretion was measured in urine and blood.
| percentage of filtered lithium excreted | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Week 1 | 0.3 ± 6.9 | -2.3 ± 16.8 |
| Week 12 | 0.8 ± 11.0 | -4.9 ± 16.6 |
The difference in iohexol-measured GFR with ertugliflozin vs. placebo. 5ml bolus iohexol (Omnipaque 300mg) was infused intravenously over 2 minutes while participants were supine. Iohexol disappearance curve was used to measure GFR over from 2-4 hours after infusion.
| mL/min/1.73 m2 | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Glomerular Filtration Rate (GFR) | 48.6 ± 4.0 | 50.1 ± 4.2 |
The difference in ERPF with ertugliflozin vs. placebo. Paraaminohippurate (PAH) was intravenously administered to measured ERPF.
| mL/min/1.73 m2 | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Effective Renal Plasma Flow (ERPF) | 399.1 ± 46.8 | 335.6 ± 41.5 |
The difference in seated SBP with ertugliflozin vs. placebo
| mmHg | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Systolic Blood Pressure (SBP) | 132 ± 5 | 128 ± 5 |
The difference in seated DBP with ertugliflozin vs. placebo
| mmHg | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Diastolic Blood Pressure (DBP) | 77 ± 3 | 76 ± 3 |
The difference in seated HR with ertugliflozin vs. placebo
| bpm | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Heart Rate (HR) | 74 ± 3 | 72 ± 3 |
Echocardiography for markers of systolic and diastolic function
| percentage of output | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| LV Ejection Fraction | 49.2 ± 4.4 | 43.6 ± 5.4 |
Arterial Stiffness using SphygmaCor software. Pulse points measured at carotid and femoral arteries.
| m/s | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Carotid-femoral Pulse Wave Velocity | 11.50 ± 1.50 | 12.14 ± 1.42 |
Plasma volume will be measured using a non-radioactive technique (indocyanine green dilution)
| ml | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Plasma Volume | 3470.9 ± 438 | 3158.2 ± 491.9 |
Extracellular water will be measured non-invasively using bioimpedence spectroscopy
| L | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Extracellular Water | 20.1 ± 0.9 | 21.8 ± 1.0 |
Cardiac output will also be measured using non-invasive cardiac monitoring (NICOM)
| L/min | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Cardiac Output | 5.8 ± 0.3 | 5.8 ± 0.3 |
Systemic vascular resistance will also be measured using non-invasive cardiac monitoring (NICOM)
| dynes·s·cm5 | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Systemic Vascular Resistance | 1346.7 ± 99.1 | 1437.1 ± 99.9 |
Neurohormones/biomarkers
| pg/ml | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Blood Angiotensin II | 89.2 ± 7.1 | 86.5 ± 7.3 |
Neurohormones/biomarkers
| pg/ml | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| BNP | 1311.1 ± 400.5 | 576.6 ± 405.3 |
Neurohormones/biomarkers
| nM | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Norepinephrine | 2.6 ± 0.3 | 2.6 ± 0.3 |
Neurohormones/biomarkers
| mM/μmol Cr | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Urinary Adenosine | 0.25 ± 0.05 | 0.39 ± 0.05 |
The difference in fractional excretion of sodium (FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.
| percentage of sodium excretion | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Week 1 | -0.6 ± 1.9 | 0.3 ± 1.7 |
| Week 12 | -0.6 ± 1.6 | 0.1 ± 1.3 |
The difference in fractional excretion of lithium and fractional excretion of sodium (calculated by the difference between FELi and FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.
| percentage of total sodium reabsorption | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Week 1 | 0.8 ± 7.0 | -2.6 ± 16.7 |
| Week 12 | 1.4 ± 10.6 | -5 ± 16.1 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertuglifozin Treatment Arm | 0/17 (0%) | 3/17 (17.6%) | 0/17 (0%) |
| Placebo Arm | 0/17 (0%) | 1/17 (5.9%) | 0/17 (0%) |
| Event | Ertuglifozin Treatment Arm | Placebo Arm |
|---|---|---|
| Heart failure hospitalizationCardiac disorders | 1/17 | 0/17 |
| EmesisGastrointestinal disorders | 1/17 | 1/17 |
| Myocardial infarctionCardiac disorders | 1/17 | 0/17 |
| Age, Continuous(years) | Ertuglifozin Treatment Arm | Placebo Arm | Total |
|---|---|---|---|
| Mean | 69.8 ± 8.7 | 69.4 ± 7.5 | 69.6 ± 7.4 |
| Sex: Female, Male(Participants) | Ertuglifozin Treatment Arm | Placebo Arm | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 15 | 13 | 28 |
| Race/Ethnicity, Customized(Participants) | Ertuglifozin Treatment Arm | Placebo Arm | Total |
|---|---|---|---|
| Caucasian | 13 | 12 | 25 |
| Black | 1 | 0 | 1 |
| Asian | 1 | 2 | 3 |
| Other | 2 | 3 | 5 |
| Region of Enrollment(participants) | Ertuglifozin Treatment Arm | Placebo Arm | Total |
|---|---|---|---|
| Canada | 8 | 8 | 16 |
| Netherlands | 9 | 9 | 18 |
| eGFR(mL/min/1.73 m2) | Ertuglifozin Treatment Arm | Placebo Arm | Total |
|---|---|---|---|
| Mean | 63.5 ± 23.3 | 66.4 ± 22.4 | 65 ± 22.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Apr 2021, 33 months.
Results were first posted in May 2025, 4 years after primary completion.
Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 33 months is close to that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin
University Health Network, Toronto →